Blurbs

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Mountain Crest Acquisition II (BTTX) and Pyxis Oncology (PYXS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Roche Holding AG (RHHVFResearch Report), Mountain Crest Acquisition II (BTTXResearch Report) and Pyxis Oncology (PYXSResearch Report) with bullish sentiments.

Roche Holding AG (RHHVF)

In a report released today, Wimal Kapadia from Bernstein maintained a Buy rating on Roche Holding AG, with a price target of CHF430.00. The company’s shares closed last Tuesday at $388.70.

Kapadia has an average return of 8.5% when recommending Roche Holding AG.

According to TipRanks.com, Kapadia is ranked #1305 out of 7928 analysts.

Roche Holding AG has an analyst consensus of Moderate Buy, with a price target consensus of $432.42, implying a 10.1% upside from current levels. In a report issued on March 17, Deutsche Bank also maintained a Buy rating on the stock with a CHF425.00 price target.

See today’s best-performing stocks on TipRanks >>

Mountain Crest Acquisition II (BTTX)

In a report released yesterday, Rahul Rakhit from LifeSci Capital maintained a Buy rating on Mountain Crest Acquisition II, with a price target of $15.00. The company’s shares closed last Tuesday at $2.10, close to its 52-week low of $2.01.

According to TipRanks.com, Rakhit ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -37.5% and a 0.0% success rate. Rakhit covers the Healthcare sector, focusing on stocks such as Nano-X Imaging, Lucira Health, and DarioHealth.

Currently, the analyst consensus on Mountain Crest Acquisition II is a Moderate Buy with an average price target of $16.50, representing a 716.0% upside. In a report issued on March 16, Chardan Capital also reiterated a Buy rating on the stock with a $18.00 price target.

Pyxis Oncology (PYXS)

LifeSci Capital analyst Adam Evertts PhD maintained a Buy rating on Pyxis Oncology yesterday and set a price target of $20.00. The company’s shares closed last Tuesday at $4.88, close to its 52-week low of $4.13.

According to TipRanks.com, PhD is ranked 0 out of 5 stars with an average return of -27.3% and a 26.3% success rate. PhD covers the Healthcare sector, focusing on stocks such as Avadel Pharmaceuticals, MEI Pharma, and Inhibrx.

Currently, the analyst consensus on Pyxis Oncology is a Moderate Buy with an average price target of $20.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on RHHVF:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos